Fig. 5: RAD51C Walker B disrupting variants, L238R and A279P, are sensitive to cisplatin and Olaparib.

RAD51C-L238R and V239G are sensitive to cisplatin and olaparib. Representative plate images of each RAD51C variant complemented cell line, RAD51C wild-type complemented cell line or parental RAD51C knockout U2OS cell line treated with increasing concentration of (a) cisplatin or (c) olaparib. Insensitive cell lines were treated with the higher dosage range (top; 0.125–2 µM) and sensitive cell lines were treated with the lower dosage range (bottom; 0.0156–0.25 µM). Colony area was quantified and normalized to the (b) untreated or (d) vehicle treated controls. Best fit dose-response curves are shown, with the mean of three to four trials plotted with standard deviation. Specific IC₅₀ values can be found in Supplementary Data 2. In (b), trials were performed four times for T120A, V166G, and knockout cells, and three times for all other cell lines. In (d), trials were performed four times for G162A, F164L, and knockout cells, and three times for all other cell lines. Source data are provided as a Source Data file.